Xeris Pharmaceuticals Inc (NASDAQ:XERS) shares were down 8.7% during trading on Wednesday following insider selling activity. The stock traded as low as $10.42 and last traded at $10.54. Approximately 529,358 shares traded hands during trading, an increase of 680% from the average daily volume of 67,902 shares. The stock had previously closed at $11.54.

Specifically, insider James E. Flynn sold 114,444 shares of the company’s stock in a transaction that occurred on Friday, January 25th. The stock was sold at an average price of $15.43, for a total value of $1,765,870.92. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Steven Prestrelski sold 15,720 shares of the company’s stock in a transaction that occurred on Wednesday, December 26th. The shares were sold at an average price of $15.82, for a total value of $248,690.40. The disclosure for this sale can be found here. Insiders sold 159,250 shares of company stock worth $2,452,644 over the last quarter.

A number of research analysts recently commented on XERS shares. Zacks Investment Research cut Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, January 12th. ValuEngine cut Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. Finally, Mizuho reiterated a “buy” rating and issued a $27.00 price objective on shares of Xeris Pharmaceuticals in a report on Tuesday, December 4th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $23.60.

The company has a debt-to-equity ratio of 0.33, a current ratio of 16.55 and a quick ratio of 16.55.

A number of large investors have recently added to or reduced their stakes in the business. Northern Trust Corp lifted its stake in Xeris Pharmaceuticals by 1.5% during the fourth quarter. Northern Trust Corp now owns 74,423 shares of the company’s stock worth $1,265,000 after purchasing an additional 1,089 shares in the last quarter. New York State Common Retirement Fund acquired a new position in Xeris Pharmaceuticals during the fourth quarter worth $66,000. Bank of New York Mellon Corp lifted its stake in Xeris Pharmaceuticals by 33.7% during the fourth quarter. Bank of New York Mellon Corp now owns 19,941 shares of the company’s stock worth $339,000 after purchasing an additional 5,027 shares in the last quarter. Geode Capital Management LLC lifted its stake in Xeris Pharmaceuticals by 23.0% during the fourth quarter. Geode Capital Management LLC now owns 82,692 shares of the company’s stock worth $1,405,000 after purchasing an additional 15,459 shares in the last quarter. Finally, BlackRock Inc. acquired a new position in Xeris Pharmaceuticals during the second quarter worth $475,000. Institutional investors own 50.48% of the company’s stock.

WARNING: “Xeris Pharmaceuticals (XERS) Shares Down 8.7% Following Insider Selling” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/xeris-pharmaceuticals-xers-shares-down-8-7-following-insider-selling/2818997.html.

About Xeris Pharmaceuticals (NASDAQ:XERS)

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

See Also: Marijuana Stocks Future Looks Bright

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.